Filed - Glenmark

More documents

Recommendations

Info

Financials and Projections Milestone Projections (in Mn USD) Revenues In USD Mn* 7 31 69 GRC 3886 7 M USD GRC 8200 31 M USD All Milestones 69 M USD FY 2006 FY 2007 FY 2008 Note 1 : We believe that we will receive 3886 milestone in FY 2007; however due to Forest’s recent statement and conservative accounting principles, we have taken the milestone into next year Note 2 : Figures for Milestones now include only those pertaining to GRC 3886 (Oglemilast) and 8200 * In USD Mn (Assumed exchange rate of 44.28 for FY06 and ~45.20 INR/USD and ~ 1.26 EUR/USD for FY07 and FY08) 29
Financials and Projections – Summary Revenues In USD Mn* Business Mix 24 13 171 7 22 90 Projections (in Mn USD) 17 279 397 CAGR ~ 52% 31 40 98 33 34 43 69 55 108 49 47 75 FY 2006 FY 2007 FY 2008 Net profit (Mn. USD) 20.5 62 115 EPS (INR) 7.28 23.60 43.78 P/E (Based on Rs. 393 Sh Price as of 26.10.06) 53.95 16.64 8.97 NCE API India Formulation ROW Latam USA CAGR ~ 137% * In USD Mn (Assumed exchange rate of 44.28 for FY06 and ~45.20 INR/USD and ~ 1.26 EUR/USD for FY07 and FY08) 30
Page 2 and 3: Disclaimer This presentation has be
Page 4 and 5: Background History 29-year old com
Page 6 and 7: Strategic roadmap: Transform into a
Page 8 and 9: Research and Development 5
Page 10 and 11: Licensing Strategy Partner Selectio
Page 12 and 13: NCE Pipeline Lead Target Indication
Page 14 and 15: NCE Pipeline Lead Target Indication
Page 16 and 17: Generic Formulations 13
Page 18 and 19: USA - Generic Formulations Current
Page 20 and 21: Europe - Start-up phase Strategy &
Page 22 and 23: Latin America Going forward Exp
Page 24 and 25: India Formulations Current Status
Page 26 and 27: India Formulations Moving forward,
Page 28 and 29: Active Pharmaceutical Ingredients C
Page 30 and 31: Financials and Projections Performa
Page 34 and 35: Summary 31
Page 36: Thank you 33

Filed - Glenmark

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?